Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (opens new window)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Źródło‎: Hemoglobin 2014;38(1):44-8.

Indeks‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (opens new window)

Hydroxyurea in thalassemia intermedia--a promising therapy. (opens new window)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Źródło‎: Ann Hematol 2005;84(7):441-6.

Indeks‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (opens new window)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (opens new window)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Źródło‎: J Clin Pathol 2010;63(2):147-50.

Indeks‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (opens new window)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (opens new window)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Źródło‎: Eur J Haematol 2009;82(3):213-8.

Indeks‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (opens new window)

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. (opens new window)

Karimi M, Darzi H, Yavarian M.

Źródło‎: J Pediatr Hematol Oncol 2005;27(7):380-5.

Indeks‎: PubMed 16012328

https://www.ncbi.nlm.nih.gov/pubmed/16012328 (opens new window)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (opens new window)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Źródło‎: Eur J Haematol 2010;84(1):52-8.

Indeks‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (opens new window)

The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. (opens new window)

Koc A, Gumruk F, Gurgey A.

Źródło‎: Pediatr Hematol Oncol 2003;20(6):429-34.

Indeks‎: PubMed 14631615

https://www.ncbi.nlm.nih.gov/pubmed/14631615 (opens new window)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (opens new window)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Źródło‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeks‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (opens new window)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (opens new window)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Źródło‎: Acta Haematol 2004;111(4):189-95.

Indeks‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (opens new window)

Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. (opens new window)

Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR.

Źródło‎: Eur J Haematol 2013;91(6):522-33.

Indeks‎: PubMed 23927461

DOI‎: 10.1111/ejh.12182

https://www.ncbi.nlm.nih.gov/pubmed/23927461 (opens new window)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (opens new window)

Perrine SP.

Źródło‎: Pediatr Ann 2008;37(5):339-46.

Indeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (opens new window)

Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. (opens new window)

Rachmilewitz EA, Aker M, Perry D, Dover G.

Źródło‎: Br J Haematol 1995;90(2):341-5.

Indeks‎: PubMed 7794754

https://www.ncbi.nlm.nih.gov/pubmed/7794754 (opens new window)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (opens new window)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Źródło‎: Br J Haematol 2011;154(2):281-4.

Indeks‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (opens new window)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (opens new window)

Thein SL.

Źródło‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indeks‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (opens new window)

Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. (opens new window)

Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R.

Źródło‎: Evid Based Complement Alternat Med 2009;6(2):141-51.

Indeks‎: PubMed 18955291

DOI‎: 10.1093/ecam/nem139

https://www.ncbi.nlm.nih.gov/pubmed/18955291 (opens new window)

A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. (opens new window)

Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP.

Źródło‎: Br J Haematol 2013;161(4):587-93.

Indeks‎: PubMed 23530969

DOI‎: 10.1111/bjh.12304

https://www.ncbi.nlm.nih.gov/pubmed/23530969 (opens new window)

Butyric acid: what is the future for this old substance? (opens new window)

Sossai P.

Źródło‎: Swiss Med Wkly 2012;142:w13596.

Indeks‎: PubMed 22674349

DOI‎: 10.4414/smw.2012.13596

https://www.ncbi.nlm.nih.gov/pubmed/22674349 (opens new window)